Antengene Corporation Limited (HKG:6996)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
5.10
+0.03 (0.59%)
Apr 29, 2026, 4:08 PM HKT
72.30%
Market Cap 3.44B
Revenue (ttm) 117.22M
Net Income (ttm) -266.11M
Shares Out 679.24M
EPS (ttm) -0.42
PE Ratio n/a
Forward PE 10.79
Dividend n/a
Ex-Dividend Date n/a
Volume 925,039
Average Volume 2,689,071
Open 5.30
Previous Close 5.07
Day's Range 5.02 - 5.30
52-Week Range 2.60 - 8.16
Beta 0.34
RSI 47.97
Earnings Date Mar 20, 2026

About Antengene Corporation

Antengene Corporation Limited, a clinical-stage APAC biopharmaceutical company, develops novel oncology therapies in Greater China and internationally. The company’s commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse large B-cell lymphoma, and multiple myeloma (MM) in adult patients. Its late-stage products candidates comprise ATG-008 (onatasertib), an mTOR inhibitor f... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Employees 129
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 6996
Full Company Profile

Financial Performance

In 2025, Antengene Corporation's revenue was 105.34 million, an increase of 14.56% compared to the previous year's 91.95 million. Losses were -239.13 million, -25.10% less than in 2024.

Financial numbers in CNY Financial Statements

News

Antengene Corporation Transcript: Status update

Announced a global licensing deal with UCB for ATG-201, securing $80 million upfront and up to $1.2 billion in milestones, with Antengene conducting initial phase I trials and UCB leading global development. The AnTenGager platform underpins a robust pipeline and supports future collaborations.

2 months ago - Transcripts

Antengene Secures Malaysian Approval For XPOVIO In Relapsed/Refractory DLBCL

(RTTNews) - Antengene Corporation Limited (6996.HK) announced that the Malaysian National Pharmaceutical Regulatory Agency has approved a supplemental New Drug Application (sNDA) for XPOVIO (selinexor...

4 months ago - Nasdaq

Antengene: NMPA Approves IND Application For Phase Ib/II CLINCH-2 Study With ATG-022

(RTTNews) - Antengene Corporation Limited (6996.HK) announced that China National Medical Products Administration or NMPA has approved the investigational new drug application for the Phase Ib/II CLIN...

5 months ago - Nasdaq